Print Page   |   Sign In   |   Join Today
News & Press: Company News

ImmunArray Announces Key Addition to Executive Team

Monday, January 29, 2018  
Share |
ImmunArray, a privately held molecular device company dedicated to the development of novel, blood-based in vitro diagnostic tests, announces a key addition to its Executive and Scientific Team. Francisco R. Velázquez, M.D., S.M., has joined the Executive Management team on a part-time basis as a Senior Scientific and Business Development Advisor.

Dr. Velázquez is the former President and Chief Executive Officer for PAML and PAML Ventures, a healthcare solutions company with a focus in diagnostics, and one of the top ten reference laboratories in the country. Prior to his role at PAML, Dr. Velázquez held numerous clinical, academic, and executive positions in healthcare systems, academic institutions, integrated delivery systems, and publicly traded companies.

He received his training at the Mallory Institute of Pathology in Boston and the Boston University Medical Center. Subsequently, he obtained a Masters in Healthcare Management at Harvard University. In addition to being a nationally known Pathologist and Physician Executive, Dr. Velázquez has significant expertise in mergers, acquisitions, financial turn-around, and system integration. He has written and lectured extensively on Health Care Economics, Consumerism in Healthcare, Life Sciences Technology, Intergenerational Impact in Health Care, and Economic Development. He is a member of numerous boards for professional organizations, and nonprofit organizations.

“Dr. Velazquez is a highly respected and long time colleague of several members of our executive group. We are excited about his contributions to our strategy and his decision to work with earlier stage technologies after leaving PAML. Our management team and Board of Directors are extremely pleased that he has agreed to join us as we take the company to its next stage of growth,” states Donna Edmonds the Chairman and CEO of ImmunArray.

"ImmunArray brings to the market breakthrough technology that will significantly impact the outcomes of patients with autoimmune disorders and many other conditions. The opportunity to contribute some of my time to the efforts that will make this technology widely available for patients worldwide, as well as working with renowned industry leaders is extremely exciting" states Dr. Velázquez.

The diagnosis and treatment of lupus is not simply an American challenge but one that affects populations around the world. For example, the Chinese population has the second largest incidence of lupus in the world with over 1 million patients identified with lupus in that country today. ImmunArray is working closely with Peter Lipsky, M.D., co-founder of AMPEL with whom ImmunArray announced a Strategic Partnership on World Lupus Day in May 2017.

The company is also expanding discussions with Leading Providers in the UK.

more Events

Southwest Virginia Life Science Forum 2018

Premium Members

Membership Software Powered by YourMembership  ::  Legal